News & Events zu Edap Tms SA (FOCL)FOCLEdap Tms SA

Major Averages Broadly Lower Near Noon

The major averages were broadly lower near noon as investors continue to balance easing inflation pressures and strong corporate earnings against renewed geopolitical risks.The inflation backdrop remains supportive for equities. July CPI and PPI both came in softer than expected, reducing concerns that the Federal Reserve will need to raise interest rates at its September meeting. PPI was unchanged in July after declining 0.1% in June, while the latest CPI data showed inflation continuing to moderate. The market is increasingly focused on whether the combination of cooling inflation and a weakening labor market will give the Fed room to ease policy later this year.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Applied Materialsreportedand provided upbeat Q4 earnings guidanceU.S. President Donald Trumpand their parts and componentsRedditwasAvalonBayin the S&P 500 at the August 18 openTeslaredesigned Roadster may have flying capabilities,OpenAI is on pace to generate annualized revenue of over $40B based on its present performance,2. WALL STREET CALLS:New StreetMicronto Buy, sees multi-trillion market cap by 2030SanDiskwith a raised Overweight rating at JPMorganCiscoto Hold at HSBCWayfairto Outperform at BernsteinFox Corp.to Overweight at Wells Fargo and JPMorgan3. AROUND THE WEB:Nokiais closing its research and development unit in Hangzhou, China, and cutting 1,600 jobs, Helsingin saysCharter Communicationsreceived final approval from California regulators to buy Cox Communications for $21.9B, WSJ reportsGoldman Sachsis courting investors to participate in Nvidia's$500B AI infrastructure financing initiative, leveraging its longstanding Nvidia relationship to secure a key role in mobilizing capital for the AI buildout, Reuters saysBPand UAE-based XRG have secured an exploration and production license for Venezuela's Loran offshore gas field, which holds an estimated 4 trillion cubic feet of recoverable gas and straddles the Venezuela-Trinidad and Tobago maritime boundary, WSJ reportsApplehas trained a large language model in partnership with Alibabafor China's market, Reuters reports4. MOVERS:Capricor Therapeuticsgains afterand announcing the FDA is "willing" to review the company's BLA amendment for its HOPE-3 studyValnevaincreases in New York after announcing with Pfizerthat the EMA has validated theIntermexhigher after providing an update on itsfor Western Union'spending acquisition of the companyKinderCarefalls afterand cutting its guidance for FY26Merlinand York Space Systemslower in New York after5. EARNINGS/GUIDANCE:Heartflowand raised its outlook for FY26Midera Food, with CEO Mark Salman commenting, "We saw continued momentum in the second quarter, with orders up 16% and the backlog reaching $446 million"Teamsharesand backed its outlook for FY26DLocal, with CEO Pedro Arnt commenting, "TPV growth has remained above 50% year-over-year for seven consecutive quarters, with the last three quarters at or above 70%"FocalThericsand backed its outlook for FY26INDEXES:Near midday, the Dow was down 0.19%, or 103.36, to 53,736.63, the Nasdaq was down 0.48%, or 128.01, to 26,675.02, and the S&P 500 was down 0.21%, or 16.73, to 7,782.26.

Company Announces ESWL and Distribution Segments as Discontinued Operations

The company said, "During the second quarter of 2026, the ESWL and Distribution segments met the criteria to be classified as held for sale under ASC 205-20, Presentation of Financial Statements - Discontinued Operations, and ASC 360-10, Property, Plant, and Equipment, and the Company determined that the planned exit represents a strategic shift that will have a significant effect on the Company's operations and financial results. Accordingly, the Company's unaudited financial results as of and for the three and six months ended June 30, 2026 reflect the Company's ESWL and Distribution operating segments as discontinued operations."

FocalTherics Q2 Revenue at $13.2M, Below Expectations

Reports Q2 revenue $13.2M, consensus $15.08M. "We continue to demonstrate commercial success with our strongest second quarter ever, reflecting the growing strength of our core business and further supporting the strategic shift to Focal Therapy with our corporate rebranding to FocalTherics," said Ryan Rhodes, CEO of FocalTherics. "Along with strong commercial momentum, we are also pleased with the developing progress of the endometriosis commercial launch in Europe and look forward to establishing additional Focal One programs to increase access to an important, non-surgical option for women with this highly debilitating condition. In addition, with expected proceeds from our ongoing capital raise, we will continue to accelerate commercial adoption in the global prostate cancer market while leveraging our multi-indication Focal One platform to grow market opportunities in treating endometriosis and expanding into benign prostatic hyperplasia or BPH. We will also continue to invest in our innovation and product development initiatives driving advances in AI-assisted treatments, FocalConnect telecollaboration technology, and integrating histotripsy together with HIFU on our Focal One platform."